Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cellectis SA ( (CLLS) ) has provided an announcement.
On October 16, 2025, Cellectis hosted an R&D Day in New York City, where the company presented the full Phase 1 dataset and outlined the pivotal Phase 2 trial design for lasme-cel (UCART22) in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This event highlighted the commercial opportunities and strategic advancements in their pipeline, reinforcing Cellectis’ position in the biotechnology industry as a leader in gene-editing therapies. The presentation of the Phase 1 data and the strategy for Phase 2 trials are significant for stakeholders, as they indicate potential market opportunities and the company’s progress in developing effective treatments for cancer.
The most recent analyst rating on (CLLS) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s overall stock score is driven by positive technical momentum and encouraging earnings call sentiment, particularly regarding clinical trial progress and strategic partnerships. However, financial performance challenges and valuation uncertainties due to ongoing losses weigh on the score.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis is a clinical-stage biotechnology company that utilizes a pioneering gene-editing platform to develop life-saving cell and gene therapies. The company focuses on an allogeneic approach for CAR T immunotherapies in oncology, offering off-the-shelf, ready-to-use gene-edited CAR T-cells to treat cancer patients. Cellectis controls the entire cell and gene therapy value chain with in-house manufacturing capabilities and is headquartered in Paris, France, with additional locations in New York and Raleigh, NC. The company is listed on the Nasdaq Global Market and Euronext Growth.
Average Trading Volume: 173,151
Technical Sentiment Signal: Hold
Current Market Cap: $304.6M
For an in-depth examination of CLLS stock, go to TipRanks’ Overview page.